
Handful of new children’s meds on the horizon. But will they be accessible to children in LMICs?
ACCESS TO MEDICINE FOUNDATION REPORT New analysis: Just 7% of pharmaceutical companies’ R&D is for children under 12, despite significant gaps in paediatric treatment options. Out of more than a thousand R&D projects assessed in the 2021 Access to Medicine Index, only 69 are for